JP2016508989A - オストワルド熟成を制御するための動的懸濁乾燥(dsd) - Google Patents
オストワルド熟成を制御するための動的懸濁乾燥(dsd) Download PDFInfo
- Publication number
- JP2016508989A JP2016508989A JP2015552139A JP2015552139A JP2016508989A JP 2016508989 A JP2016508989 A JP 2016508989A JP 2015552139 A JP2015552139 A JP 2015552139A JP 2015552139 A JP2015552139 A JP 2015552139A JP 2016508989 A JP2016508989 A JP 2016508989A
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- particles
- drying
- high pressure
- pharmaceutical ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 71
- 238000001016 Ostwald ripening Methods 0.000 title claims abstract description 39
- 238000001035 drying Methods 0.000 title claims description 29
- 239000002245 particle Substances 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 69
- 238000000265 homogenisation Methods 0.000 claims abstract description 32
- 230000008569 process Effects 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000003381 stabilizer Substances 0.000 claims abstract description 17
- 238000002955 isolation Methods 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims description 31
- 239000012296 anti-solvent Substances 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000010951 particle size reduction Methods 0.000 claims description 2
- 239000005426 pharmaceutical component Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000009826 distribution Methods 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960004123 mometasone furoate monohydrate Drugs 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AQCCVUHZMIMSIB-HRVPQZBTSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate;hydrate Chemical compound O.O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 AQCCVUHZMIMSIB-HRVPQZBTSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012369 In process control Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000034655 secondary growth Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- CZPILLBHPRAPCB-AREMUKBSSA-N tarazepide Chemical compound O=C([C@@H](NC(=O)C=1N2CCCC=3C=CC=C(C2=3)C=1)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 CZPILLBHPRAPCB-AREMUKBSSA-N 0.000 description 1
- 229950010940 tarazepide Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Images
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B3/00—Drying solid materials or objects by processes involving the application of heat
- F26B3/02—Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air
- F26B3/10—Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B1/00—Preliminary treatment of solid materials or objects to facilitate drying, e.g. mixing or backmixing the materials to be dried with predominantly dry solids
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B3/00—Drying solid materials or objects by processes involving the application of heat
- F26B3/02—Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air
- F26B3/10—Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it
- F26B3/12—Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it in the form of a spray, i.e. sprayed or dispersed emulsions or suspensions
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、粒径の増減が起こらないような穏やかな条件下で高圧ホモジナイゼーションを使用することによって、安定化剤を添加する必要なく粒子懸濁液中で起こるオストワルド熟成現象を制御し、それにより乾燥粉末の形態での単離工程中の懸濁液の安定化を可能にするための方法に関する。
(オストワルド熟成現象)
オストワルド熟成(Rawlinsの論文、1982;Muller及びBohmの論文、1998)は、超微細分散系について記載されており、結晶成長の原因となり、したがって粒径分布(particle size distribution)(PSD)の平均径を増大させる。オストワルド熟成は、小粒子と大粒子との間の溶解溶解度の差異によって引き起こされる。これは実際には、より大きい粒子と比較して、非常に小さい粒子のより高い飽和溶解度に基づく効果である。分子は、小粒子の周りのより高い濃縮された(飽和溶解度がより高い)領域から、より低い薬物濃度を有するより大きい粒子の周りの領域に拡散する。これにより、大きい粒子の周りで過飽和溶液が形成され、したがって、薬物が結晶化し、大きい粒子が成長する。小粒子から大粒子への薬物の拡散プロセスは、小粒子の周りにこれ以上飽和しない領域を残し、それにより小粒子から薬物が溶解し、最終的に小粒子が完全に消失する(V. B. Patravaleの論文、2004)。
経時的に粒径分布の平均径を増大させるこの現象の存在は、懸濁液の不安定挙動をもたらし、したがって、(乾燥粉末を単離するために)懸濁液を乾燥している間に、粒径分布がシフトする傾向にもなり、結果として、最終生成物の生物学的利用能、毒性、及び有効性に影響し得る。
懸濁液中のオストワルド熟成を防止する一般的な方法としては、元の懸濁液への安定化剤の添加がある。
a)水混和性有機溶媒中の実質的に水不溶性のAPI及び阻害剤の溶液を生成する工程;
b)水及び安定剤を含む水相を添加し、阻害剤及びAPIを含む固形粒子を沈殿させる工程
を含む。
したがって、本発明は、懸濁液中の医薬成分の粒子を処理するための方法であって:
a)高圧ホモジナイゼーション装置を使用することによって、高圧条件下で懸濁液中の医薬成分の粒径を低減する工程と;
b)粉末の形態で懸濁液から粒子を単離する工程であり、単離工程中に、懸濁液の少なくとも一部が穏やかな圧力条件で高圧ホモジナイゼーション装置にリサイクルされることを特徴とする、工程と
を含む方法を提供する。
(1)医薬成分及び逆溶媒の懸濁液を形成するためのフィード容器と;
(2)所望の粒径を得るためにリサイクルモードで作動することができる高圧ホモジナイゼーション装置と;
(3)乾燥粉末の形態で粒子を単離するための懸濁液乾燥デバイスと
を備え、粒子を単離する工程中に懸濁液の少なくとも一部が穏やかな圧力の条件で高圧ホモジナイゼーション装置にリサイクルされるように構成されている、前記装置を提供する。
本発明は、最適化された穏やかな圧力の条件で高圧ホモジナイゼーション(HPH)を使用して粒子懸濁液中のオストワルド熟成現象を制御するための方法に関する。
a)オストワルド熟成に起因する粒径のいずれの増大も、穏やかな圧力の条件でのリサイクル手順及び後続のHPHの安定化効果によって防止され;
b)穏やかな条件では粒子成長のみが防止されるので、粒径のさらなる低減が起こらない
ように慎重に選択される必要がある。
高圧ホモジナイゼーション(HPH)は、懸濁液中の粒子のミクロンサイズへの細分化を伴う流体の機械的なプロセスである。
1.モメタゾンフロ酸エステル一水和物(2330g)を水(23000g)に懸濁させ、5時間撹拌することによって均一な懸濁液を得;その後、これを、リサイクルモード(HPHの排出物を撹拌された容器の入口に戻す)で757.5〜1363.5バールの範囲の圧力にて作動する実験室規模のHPH装置に送り、作動して63時間後にDv50約2μmでこの工程を終わらせた。
Claims (21)
- 懸濁液中の医薬成分の粒子を処理するための方法であって:
a)高圧ホモジナイゼーション装置を使用することによって、高圧条件下で該懸濁液中の該医薬成分の粒径を低減する工程と;
b)粉末の形態で該懸濁液から該粒子を単離する工程であって、該単離工程中に、該懸濁液の少なくとも一部が穏やかな圧力の条件下で該高圧ホモジナイゼーション装置にリサイクルされることを特徴とする工程とを含む、前記方法。 - 前記高圧条件が、500〜3500バールの範囲の圧力である、請求項1記載の方法。
- 前記穏やかな圧力の条件が、前記粒径低減に適用される前記高圧より低い圧力である、請求項1記載の方法。
- 前記穏やかな圧力の条件が500バール未満である、請求項1又は2記載の方法。
- 前記高圧ホモジナイゼーション装置が、ギャップバルブ、ローターステーター、超音波、ホモジナイゼーションセル、又は高シア流体処理を備える、請求項1から4のいずれか一項記載の方法。
- 前記粒子単離工程が、乾燥粉末の形態で前記粒子を得るための乾燥プロセスを含む、請求項1から5のいずれか一項記載の方法。
- 前記乾燥プロセスが、噴霧乾燥、凍結乾燥、蒸発乾燥、又は流動床乾燥工程を含む、請求項6記載の方法。
- 前記乾燥工程が噴霧乾燥プロセスである、請求項7記載の方法。
- 前記懸濁液が、逆溶媒に前記医薬成分を添加することによって形成される、請求項1から8のいずれか一項記載の方法。
- 前記逆溶媒が、前記医薬成分が溶解度をまったく示さず、又は低い溶解度を示す任意の媒体、好ましくはメタノール、エタノール、アセトン、酢酸エチル、n-ヘプタン、又は水である、請求項9記載の方法。
- 前記懸濁液が、最適化された穏やかな圧力の条件でHPHユニットに連続的にリサイクルされる、請求項1から10のいずれか一項記載の方法。
- 前記懸濁液が、安定化剤又は界面活性剤を含有しない、請求項1から11のいずれか一項記載の方法。
- 前記粒子単離工程中に、処理時間ウィンドウ制限がない、請求項1から12のいずれか一項記載の方法。
- 前記粒径が、前記医薬成分単離工程中に安定化される、請求項1から13のいずれか一項記載の方法。
- 請求項1から14のいずれか一項記載の方法によって得られる粒子。
- 請求項15に記載の粒子を含む医薬製剤。
- 懸濁液中の医薬成分の粒子を処理するための装置であって:
(1)該医薬成分及び逆溶媒の懸濁液を形成するためのフィード容器と;
(2)所望の粒径を得るためにリサイクルモードで作動することができる高圧ホモジナイゼーション装置と;
(3)乾燥粉末の形態で該粒子を単離するための懸濁液乾燥デバイスと
を備え、粒子を単離する工程中に該懸濁液の少なくとも一部が穏やかな圧力の条件で該高圧ホモジナイゼーション装置にリサイクルされるように構成されている、前記装置。 - 前記高圧ホモジナイゼーション装置が、ギャップバルブ、ローターステーター、超音波、ホモジナイゼーションセル、又は高シア流体処理を備える、請求項17記載の装置。
- 前記懸濁液乾燥デバイスが、乾燥プロセス、例えば、噴霧乾燥、凍結乾燥、蒸発乾燥、又は流動床乾燥工程などを実施するためのデバイスを備える、請求項17又は18記載の装置。
- 高圧ホモジナイゼーションプロセスを使用して医薬成分の懸濁液から粉末形態で該医薬成分の粒子を得るプロセスにおいて、オストワルド熟成を防止する方法であって、該懸濁液から該粒子を単離する工程中に穏やかな圧力の条件で該懸濁液の少なくとも一部をリサイクルする工程を含む、前記方法。
- 高圧ホモジナイゼーションプロセスを使用して医薬成分の懸濁液から粉末形態で該医薬成分の粒子を得るプロセスにおけるオストワルド熟成を防止するための、該懸濁液から該粒子を単離する工程中に穏やかな圧力の条件で該懸濁液の少なくとも一部をリサイクルする工程の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT106738 | 2013-01-09 | ||
PT106738A PT106738B (pt) | 2013-01-09 | 2013-01-09 | Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico |
PCT/GB2014/050055 WO2014108687A1 (en) | 2013-01-09 | 2014-01-09 | Dynamic suspension drying (dsd) to control ostwald ripening |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016508989A true JP2016508989A (ja) | 2016-03-24 |
JP2016508989A5 JP2016508989A5 (ja) | 2017-02-09 |
JP6316847B2 JP6316847B2 (ja) | 2018-04-25 |
Family
ID=49999991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015552139A Expired - Fee Related JP6316847B2 (ja) | 2013-01-09 | 2014-01-09 | オストワルド熟成を制御するための動的懸濁乾燥(dsd) |
Country Status (13)
Country | Link |
---|---|
US (1) | US10151529B2 (ja) |
EP (1) | EP2874609B1 (ja) |
JP (1) | JP6316847B2 (ja) |
CN (1) | CN105007900B (ja) |
BR (1) | BR112015016605B1 (ja) |
CA (1) | CA2897277C (ja) |
DK (1) | DK2874609T3 (ja) |
ES (1) | ES2659968T3 (ja) |
HU (1) | HUE036691T2 (ja) |
IL (1) | IL239845B (ja) |
PT (1) | PT106738B (ja) |
SG (1) | SG11201505370RA (ja) |
WO (1) | WO2014108687A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531162A (ja) * | 2000-04-20 | 2003-10-21 | スカイファーマ・カナダ・インコーポレーテッド | 改善された水不溶性薬剤粒子の処理 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
DE69433723T3 (de) * | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen |
US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
CA2684454A1 (en) * | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6318649B1 (en) * | 1999-10-06 | 2001-11-20 | Cornerstone Technologies, Llc | Method of creating ultra-fine particles of materials using a high-pressure mill |
AU2001270302A1 (en) * | 2000-07-06 | 2002-01-21 | Cornerstone Technologies, L.L.C. | Multi-stage size reduction, blending and drying system and method |
DE60220923T2 (de) * | 2001-08-06 | 2008-03-06 | Astrazeneca Ab | Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct) |
AU2003283954A1 (en) * | 2002-12-06 | 2004-06-30 | Cornerstone Technologies, L.L.C. | High g mill in a blending and drying system |
EP2054036B1 (en) * | 2006-07-24 | 2019-12-18 | Singh-Broemer and Company, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
PT105058B (pt) * | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
-
2013
- 2013-01-09 PT PT106738A patent/PT106738B/pt active IP Right Grant
-
2014
- 2014-01-09 CA CA2897277A patent/CA2897277C/en active Active
- 2014-01-09 JP JP2015552139A patent/JP6316847B2/ja not_active Expired - Fee Related
- 2014-01-09 HU HUE14701124A patent/HUE036691T2/hu unknown
- 2014-01-09 BR BR112015016605-9A patent/BR112015016605B1/pt active IP Right Grant
- 2014-01-09 CN CN201480011112.5A patent/CN105007900B/zh active Active
- 2014-01-09 DK DK14701124.1T patent/DK2874609T3/en active
- 2014-01-09 US US14/760,095 patent/US10151529B2/en active Active
- 2014-01-09 SG SG11201505370RA patent/SG11201505370RA/en unknown
- 2014-01-09 ES ES14701124.1T patent/ES2659968T3/es active Active
- 2014-01-09 EP EP14701124.1A patent/EP2874609B1/en active Active
- 2014-01-09 WO PCT/GB2014/050055 patent/WO2014108687A1/en active Application Filing
-
2015
- 2015-07-08 IL IL239845A patent/IL239845B/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531162A (ja) * | 2000-04-20 | 2003-10-21 | スカイファーマ・カナダ・インコーポレーテッド | 改善された水不溶性薬剤粒子の処理 |
Also Published As
Publication number | Publication date |
---|---|
WO2014108687A1 (en) | 2014-07-17 |
US10151529B2 (en) | 2018-12-11 |
CA2897277C (en) | 2020-09-01 |
EP2874609A1 (en) | 2015-05-27 |
BR112015016605B1 (pt) | 2022-11-29 |
BR112015016605A2 (pt) | 2017-07-11 |
SG11201505370RA (en) | 2015-08-28 |
CN105007900A (zh) | 2015-10-28 |
ES2659968T3 (es) | 2018-03-20 |
IL239845A0 (en) | 2015-08-31 |
EP2874609B1 (en) | 2017-12-27 |
JP6316847B2 (ja) | 2018-04-25 |
PT106738B (pt) | 2015-06-08 |
CA2897277A1 (en) | 2014-07-17 |
HUE036691T2 (hu) | 2018-07-30 |
IL239845B (en) | 2019-05-30 |
DK2874609T3 (en) | 2018-04-09 |
PT106738A (pt) | 2014-07-09 |
US20150354891A1 (en) | 2015-12-10 |
CN105007900B (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015212618B2 (en) | Assisted particle size reduction process | |
Galisteo-González et al. | Systematic study on the preparation of BSA nanoparticles | |
Gao et al. | Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system | |
Geetha et al. | Various techniques for preparation of nanosuspension-a review | |
Zhong et al. | Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment | |
US7754777B2 (en) | Method for obtaining micro- and nano-disperse systems | |
Esfandiari et al. | Ampicillin nanoparticles production via supercritical CO 2 gas antisolvent process | |
Muhrer et al. | Precipitation of lysozyme nanoparticles from dimethyl sulfoxide using carbon dioxide as antisolvent | |
Che et al. | Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs. | |
Jafari et al. | Gas-antisolvent (GAS) crystallization of aspirin using supercritical carbon dioxide: experimental study and characterization | |
JP6310636B2 (ja) | マイクロ流体化処理によって作製された難溶性薬物のナノ懸濁液 | |
Mlalila et al. | Effects of spray-drying on w/o/w multiple emulsions prepared from a stearic acid matrix | |
JP6316847B2 (ja) | オストワルド熟成を制御するための動的懸濁乾燥(dsd) | |
Malviya et al. | Efficiency of self‐assembled etoricoxib containing polyelectrolyte complex stabilized cubic nanoparticles against human cancer cells | |
Lehocký et al. | Occurrence and prevention of Pickering foams in pharmaceutical nano-milling | |
Chen et al. | Green preparation of uniform prednisolone nanoparticles using subcritical water | |
Ong et al. | Drug solubilization by means of a surface-modified edible biopolymer enabled by hot melt extrusion | |
Chakravorty | Nanosuspension as an emerging Nanotechnology and Techniques for its Development | |
Rowe et al. | Precipitation technologies for nanoparticle production | |
Shah et al. | Production techniques | |
US20120251595A1 (en) | Emulsion template method to form small particles of hydrophobic agents with surface enriched hydrophilicity by ultra rapid freezing | |
Tenorio et al. | Screening design of experiment applied to supercritical antisolvent precipitation of amoxicillin | |
Singh et al. | Nanosuspension: Way to enhance the bioavailability of poorly soluble drug | |
KR20090124337A (ko) | 초고압기술과 에멀젼 확산 기술을 결합한 새로운나노입자의 제조방법 | |
Botas et al. | Dynamic Suspension Drying for Ostwald Ripening Phenomena Control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180328 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6316847 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |